Treatment of Glioblastoma Multiforme with Radiotherapy and Concomitant and Adjuvant Temozolomide: Translation of Randomised Controlled Trial Evidence into Routine Clinical Practice

Clinical Oncology

Volumn 23, Issue 5, 2011, Pages 372-373

  Herbert, C ^a   Williams, M ^b   Sawyer, H ^b   Greenslade, M ^b   Cornes, P ^a   Hopkins, K ^a  

^a UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^b SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLTRANSFERASE; TEMOZOLOMIDE;

CLINICAL PRACTICE; DNA REPAIR; GLIOBLASTOMA; HUMAN; LETTER; METHYLATION; PRIORITY JOURNAL; PROMOTER REGION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY;

ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; GLIOBLASTOMA; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79955655072     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2011.01.157     Document Type: Letter

References (3)

1. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
2. Hegi M., Diserens A.C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003.
3. Sridhar T., Gore A., Boiangiu I., et al. Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: a retrospective study. Clin Oncol (R Coll Radiol) 2009, 21:19-22.